Company Profile

Freeline Therapeutics Holdings plc is a United Kingdom-based clinical-stage biotechnology company. The Company is developing transformative adeno-associated virus (AAV) vector-mediated gene therapies. It is focused on improving patient lives through one-time treatments for chronic debilitating diseases. It uses its rationally designed AAV vector and capsid (AAVS3), along with promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient's bloodstream. Therapeutic AAV vectors consist of two main components, the capsid and the expression cassette (that contains the gene and the promoter). The Company is advancing clinical programs in Fabry disease and Gaucher disease Type 1. The Company's pipeline includes Fabry Disease FLT190 for the treatment of Fabry disease and Gaucher Disease FLT201 for the treatment of type 1 Gaucher disease.

Employees

Sector

Biotechnology & Medical Research

More about the company

Aug. 21	Spur Therapeutics Limited Announces Termination of Michael John Parini from Director Appointment, Effective July 31, 2026	CI
Aug. 18	Spur Therapeutics Limited Announces Appointment of Henning Stennicke to Director, Effective August 17, 2026	CI
Jul. 14	Spur Therapeutics Announces CEO Michael Parini Will Transition to Chair of the Board of Directors, Effective July 31, 2026	CI
Jul. 14	Spur Therapeutics Announces Executive Transitions	CI
Jul. 07	Spur Therapeutics Doses First Patient In GALILEO-3 Pivotal Clinical Trial Of FLT201 For Gaucher Disease Type 1	CI
May. 04	Spur Therapeutics Presents Clinical Insights on Bone Disease Impact of Flt201 in Adults with Gaucher Disease Type 1	CI
Feb. 04	Spur Therapeutics Presents New Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease At 22Nd Annual Worthldsymposium	CI
25-10-08	Spur Therapeutics Limited Auditor Raises 'Going Concern' Doubt	CI
25-10-08	Spur Therapeutics Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-10-07	Spur Therapeutics Presents Updated Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease At ESGCT 32nd Annual Congress	CI
25-10-01	Spur Therapeutics to Present New Clinical Data on Its Gene Therapy Candidate in Gaucher Disease at Upcoming ESGCT Annual Congress	CI
25-06-06	Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson's Disease at 2025 GBA1 Meeting	CI
25-05-27	Spur Therapeutics Publishes Preclinical Proof-Of-Concept Data for FLT201, its Clinical-Stage Gene Therapy Candidate in Gaucher Disease	CI

23-11-28	HC Wainwright Downgrades Freeline Therapeutics to Neutral From Buy, Adjusts Price Target to $6.50 From $15	MT
23-10-18	Wedbush Downgrades Freeline Therapeutics to Neutral From Outperform, Cuts Price Target to $5 From $8	MT
23-10-04	Wedbush Adjusts Freeline Therapeutics Price Target to $8 From $5, Maintains Outperform Rating	MT
23-08-16	Stifel Adjusts Price Target on Freeline Therapeutics to $4 From $3, Keeps Hold Rating	MT
23-05-30	Wedbush Raises Price Target on Freeline Therapeutics to $5 From $1, Maintains Outperform Rating	MT

24-04-24	Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting	AQ
24-02-20	Acquisition of Freeline by Syncona Becomes Effective	AQ
24-02-12	Freeline Shareholders Approve Acquisition by Syncona	AQ
23-12-08	Hemophilia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 \| Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics	AQ
23-12-01	Freeline Therapeutics : Reports Second Quarter 2023 Financial Results and Business Highlights - Form 6-K	PU

23-12-13	Pharma und Gesundheit: weitere Konsolidierung
23-12-12	Farma en gezondheid: consolidatie gaat door
23-12-11	Farmaceutica e salute: continua il consolidamento
23-12-11	Farmacia y salud: La consolidación continúa
23-12-11	Pharma & santé : poursuite de la consolidation

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FREELINE THERAPEUTICS HOLDINGS PLC	-.--%	+0.93%	-	-	28.25M
WUXI APPTEC CO., LTD.	+0.65%	-3.56%	+33.53%	+60.50%	63.48B
ARGENX SE	+1.76%	+1.27%	+11.82%	+82.12%	54.55B
LONZA GROUP AG	-0.94%	+0.99%	+10.45%	+102.18%	53.59B
IQVIA HOLDINGS INC.	+2.74%	+0.76%	+27.78%	+57.33%	44.75B
BEONE MEDICINES AG	+2.21%	-3.16%	+18.12%	+100.55%	41.62B
REVOLUTION MEDICINES, INC.	+1.32%	-3.03%	+223.88%	+926.70%	39.91B
CELLTRION, INC.	+0.64%	-3.85%	+11.71%	+45.57%	32.47B
GENMAB A/S	+29.06%	+47.63%	+107.12%	+94.27%	26.7B
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	-7.45%	+24.25%	-2.99%	23.36B
Average	+4.08%	-0.42%	+52.07%	+162.92%	42.27B
Weighted average by Cap.	+3.21%	-0.29%	+47.51%	+161.56%

Freeline Therapeutics Holdings plc Stock

Stocks

FRLN

US35655L2060

Biotechnology & Medical Research

Latest news: Freeline Therapeutics Holdings plc

Analysts' recommendations: Freeline Therapeutics Holdings plc

Press Releases: Freeline Therapeutics Holdings plc

News in other languages: Freeline Therapeutics Holdings plc

Bio Therapeutic Drugs

Company Profile